RxDoctor Payments Data

Ritesh Gupta, MD

Internal Medicine · Mobile, ALNPI 1124100847

Payments from drug & device makers

$10,919in general payments, 2019–2025

Across 531 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Johnson & Johnson$1K
  • Medtronic$1K
  • Boston Scientific$1K
  • E.r. Squibb & Sons, L.L.C.$762
  • Sanofi-aventis U.S. LLC$495
  • plus $4K from 40 others

What the payments were for

  • Travel & lodging$2,10019%
  • Food & beverage$8,81981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,919 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$902,240
Medicare patients
882
Services billed
5,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban811$803,574
EntrestoSacubitril/Valsartan482$463,760
EliquisApixaban339$344,617
Repatha SureclickEvolocumab185$120,277
FarxigaDapagliflozin Propanediol135$109,588
MounjaroTirzepatide63$68,471
JardianceEmpagliflozin55$59,683
OzempicSemaglutide56$59,432
BrilintaTicagrelor32$30,400
MultaqDronedarone Hcl20$28,560
Bisoprolol Fumarate772$26,539
Atorvastatin Calcium1,533$20,825
EdarbiAzilsartan Medoxomil35$18,836
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide326$15,127
Praluent PenAlirocumab19$14,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,439$803,574811 claims
NovartisEntresto$1,576$463,760482 claims
PfizerEliquis$95$344,617339 claims
AstraZenecaFarxiga, Brilinta$449$139,988167 claims
Boehringer IngelheimJardiance$305$59,68355 claims
Novo NordiskOzempic$131$59,43256 claims
Sanofi-aventis U.S. LLCMultaq$495$28,56020 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$142$26,19752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →